Benefits of Extracorporeal Shockwave Therapy to Reduce Spasticity in Stroke/CP

August 7, 2024 updated by: Muhammad Naveed Babur, Superior University
This Study will help to explain us that ExtracorporealShockwave therapy can reduce spasticity in Stroke Patient,help them to restore their abilities and ROM.Therapy reduces dependency rate of patient.Also seen this therapy shows reduction in spasticity of CP child population.Improving the motor recovery.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

ESWT therapy increses molecular and immunological reactions,increase blood microcirculation and neurovascularization.It enhancing the neural proliferation of neural stem cell(NSC),which shows repair in brain function in CNS diseases.Extracorporeal shockwave can produce Nitric oxide in enzymatic and non enzymatic way which help, to reduce muscle spasm.Extracorporeal Shockwave reduce the exitibilty of motor neuron by vibratory stimulation of tendon and reduces tension.After 2 weeks ESWT muscle tension reduces increases range of motion reduces the pain.shock wave therapy appears to be effective in reducing spasticity levels irrespective of the age of the participants, the type of injury, and the tool used to measure the effect.ESWT change in motor neuron exitibilty & also associated with the spastic muscle.

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • Clinical setups Sargodha,Lahore,BWN

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 3rd stage of Stroke

Exclusion Criteria:

  • Non spastic CP,1st stage of Stroke,Spasticity caused by injury,Newborn

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Extracorporeal Shockwave Therapy
Diagnostic test: Extracorporeal Shockwave Therapy

" The ESTW machine is turned on and the instrument, or shockwave gun, is pressed against the affected area. Rapid impulses are then delivered to the patient. Treatment typically lasts between 5 and 15 minutes. While this treatment can be uncomfortable for some, most do not experience any pain.

Once treatment is completed, patients should do their best to physical activity… higher levels of energy Shockwaves into deeper tissue locations… ESWT therapies can help treat neurological disorders like multiple sclerosis and the effects of stroke.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Ashworth Scale MAS
Time Frame: 12 Months
The Ashworth Scale method of grading spasticity, working with Cerebral Palsy and Stroke patients. The original Ashworth scale was a 5 point numerical scale that graded spasticity from 0 to 4, with 0 being no resistance and 4 being a limb rigid in flexion or extension. In 1987, while performing a study to exam interrater reliability of manual tests of elbow flexor muscle spasticity, Bohannon and Smith modified the Ashworth scale by adding 1+ to the scale to increase sensitivity. Since its modification, the modified Ashworth scale (MAS), has been applied in clinical practice and research as a measure of spasticity.
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Superior University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Actual)

May 1, 2024

Study Completion (Estimated)

September 30, 2024

Study Registration Dates

First Submitted

August 7, 2024

First Submitted That Met QC Criteria

August 7, 2024

First Posted (Actual)

August 12, 2024

Study Record Updates

Last Update Posted (Actual)

August 12, 2024

Last Update Submitted That Met QC Criteria

August 7, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MSRSW/Batch-Fall22/735

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe